Abstract |
Current thrombolytic therapy fails to induce early, complete, and sustained reperfusion in +/-50% of the patients with ST-segment elevation acute coronary syndromes. There are two complementary approaches to improve thrombolytic therapy: the development of new fibrinolytics with enhanced fibrin specificity and/or reduced plasma clearance and the coadministration of new antithrombotic agents. The results obtained so far suggest that single-bolus fibrinolytic therapy is likely to replace the current infusions in the near future. This may result in a significantly earlier (prehospital) treatment of patients. The concomitant intravenous administration of a glycoprotein IIb/IIIa receptor antagonist (in combination with a reduced dose of a fibrinolytic) appears to be able to further enhance the efficacy for clot lysis without increasing the risk for bleeding complications.
|
Authors | F Van de Werf |
Journal | American heart journal
(Am Heart J)
Vol. 138
Issue 2 Pt 2
Pg. S115-20
(Aug 1999)
ISSN: 0002-8703 [Print] United States |
PMID | 10426869
(Publication Type: Journal Article, Review)
|
Chemical References |
- Fibrinolytic Agents
- Platelet Glycoprotein GPIIb-IIIa Complex
- Platelet Glycoprotein GPIb-IX Complex
- Platelet Membrane Glycoproteins
- Receptors, Antigen, B-Cell
- Receptors, Cell Surface
- glycoprotein receptor GPIb-IX
- Fibrin
- Tissue Plasminogen Activator
|
Topics |
- Coronary Disease
(drug therapy)
- Fibrin
(antagonists & inhibitors)
- Fibrinolytic Agents
(therapeutic use)
- Hemorrhage
(prevention & control)
- Humans
- Injections, Intravenous
- Metabolic Clearance Rate
- Myocardial Infarction
(drug therapy)
- Myocardial Reperfusion
(methods)
- Platelet Glycoprotein GPIIb-IIIa Complex
(antagonists & inhibitors)
- Platelet Glycoprotein GPIb-IX Complex
- Platelet Membrane Glycoproteins
- Receptors, Antigen, B-Cell
(antagonists & inhibitors)
- Receptors, Cell Surface
(antagonists & inhibitors)
- Substrate Specificity
- Thrombolytic Therapy
- Time Factors
- Tissue Plasminogen Activator
(therapeutic use)
|